Singulex competitors

Tom Schoenherr comes to Ambry with more than 20 years of experience in the molecular diagnostics space, most recently as the CCO of Omada Health where he was responsible for driving business growth and increasing market share. He also served in similar roles at Counsyl, Quest Diagnostics, Siemens Healthcare and Abbott Diagnostics. As Ambry’s Chief Commercial Officer, Tom will be responsible for the execution of Ambry’s goto market strategy and will oversee all commercial functions including service, support, sales, marketing, business development, managed care and genetic specialists. Tom earned his BS from Michigan State University and completed his Executive Business Development Program from the University of Notre Dame.

Bill Corl is a Chief Executive Officer at Omega Laboratories Inc and is based in Omega Laboratories Ltd.

Kevin Hrusovsky is a biotech entrepreneur and healthcare visionary who has dedicated his career to transforming medicine from reactive “sick care” to preventative and personalized healthcare. He catalyzed a precision health movement to promote innovation for eradicating disease and personalizing global health and founded Powering Precision Health, the industry’s leading platform and premier annual forum for advancing the deep science that powers precision health. Hrusovsky has been recognized as a 2017 BBJ Innovation All-Star, a three-time award finalist of the EY Entrepreneur of the Year®, and received the Lifetime Achievement Award for Leadership (2018) and E.G. Bailey Entrepreneurship Award (2013) from The Ohio State University. A dynamic speaker, Hrusovsky regularly participates at leading conferences, including the BIO International Convention, J.P. Morgan Healthcare Conference, PULSE: The Atlantic Summit on Health Care, and MedCity CONVERGE.He currently serves as President, Chairman and CEO of Quanterix, a company digitizing biomarker analysis to advance precision health. In 2017, he took Quanterix public in one of the most successful IPOs for a life science tools company in recent history. Hrusovsky is renowned for his strong track record of launching disruptive technologies, building fast-growing companies, and developing successful commercialization strategies. He lends his business expertise on the boards of several innovative technology companies and serves on the Educational Board of the Massachusetts Biotech Council the JALA Editorial Board, the Strategy Committee of Children’s Hospital Boston and more.Hrusovsky holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University. He received an Honorary Doctorate from Framingham State University and helped build competitive strategy curriculum at the Institute for Strategy & Competitiveness at Harvard Business School. Follow him on Twitter @KevinHrusovsky.

A co-founder of CBLPath via the CBL acquisition, Carlos Urmacher is certified by the American Board of Pathology in Surgical Pathology and Dermatopathology. He is a member of the U.S. and Canadian Academy of Pathology, a member of the College of American Pathologists, and a fellow of the American Society of Clinical Pathologists. Dr. Urmacher has served as a member of the Board of Trustees and Treasurer of the New York Pathological Society, as a member of the Scientific Advisory Board of the World Health Organization and as a member of the editorial boards of The American Journal of Surgical Pathology and The American Journal of Dermatopathology. Prior to joining CBL in 2000 as Co-Director and Chief of Surgical Pathology, Dr. Urmacher served as Attending Pathologist at North Shore University Hospital – NYU School of Medicine in Manhasset, New York for nine years and as Attending Pathologist at Memorial Sloan-Kettering Cancer Center and Associate Professor of Pathology at Cornell University Medical Center for 13 years. Dr. Urmacher is a frequent lecturer and has authored more than 70 articles and six medical textbook chapters. He graduated with an M.D. degree from the Central University of Venezuela and served as Chief Resident in Pathology at Mount Sinai Hospital, New York and as Chief Fellow in Pathology at Memorial Sloan-Kettering Cancer Center and New York University Hospital. Dr. Urmacher was recently giving the honor of distinguished visitor professor in Pathology by Johns Hopkins.

Benjamin Leader is a Chief Executive Officer at Reprosource Fertility Diagnostics Inc and is based in Plain, Massachusetts. He attended Harvard Medical School between 1995 and 2003.